Pentam 300
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Pentam 300
- Generic name
- PENTAMIDINE ISETHIONATE
- Manufacturer
- Fresenius Kabi USA, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- cc2b635e-4840-4dc3-a177-5484371680e8
- SPL ID
- 5fe83fb0-2b64-40a2-a996-aaa6292e661e
- Version
- 3
- Effective date
- 2022-09-13
- Source export date
- 2026-09-28
- Source partition
- 1
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/9c7783846d422acb0c9e59457606951c785a7d28cc631c8cc4839d0dc7c55f39/drug-label-0001-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:14:08
| Harmonized routes |
|---|
| INTRAMUSCULAR, INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 019264 | derived:openfda.application_number |
| application number | NDA019264 | openfda.application_number | |
| brand name | Pentam 300 | openfda.brand_name | |
| generic name | PENTAMIDINE ISETHIONATE | openfda.generic_name | |
| manufacturer name | Fresenius Kabi USA, LLC | openfda.manufacturer_name | |
| ndc | package | 63323-113-10 | openfda.package_ndc |
| ndc | package | 63323-113-01 | openfda.package_ndc |
| ndc | product | 63323-113 | openfda.product_ndc |
| ndc11 | package | 63323011301 | derived:openfda.package_ndc |
| ndc11 | package | 63323011310 | derived:openfda.package_ndc |
| rxcui | 861601 | openfda.rxcui | |
| rxcui | 861604 | openfda.rxcui | |
| spl id | 5fe83fb0-2b64-40a2-a996-aaa6292e661e | id | |
| spl set id | cc2b635e-4840-4dc3-a177-5484371680e8 | set_id | |
| unii | V2P3K60DA2 | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. Severe hypotension may result after a single IM or IV dose and is more likely with rapid IV administration (see PRECAUTIONS ). The administration of the drug should, therefore, be limited to the patients in whom Pneumocystis carinii has been demonstrated. Patients should be closely monitored for the development of serious adverse reactions (see PRECAUTIONS and ADVERSE REACTIONS ). Extravasations have been reported which, in some instances, proceeded to ulceration, tissue necrosis and/or sloughing at the injection site. While not common, surgical debridement and skin grafting has been necessary in some of these cases; long-term sequelae have been reported. Prevention is the most effective means of limiting the severity of extravasation. The intravenous needle or catheter must be properly positioned and closely observed throughout the period of pentamidine isethionate administration. If extravasation occurs, the injection should be discontinued immediately and restarted in another vein. Because there are no known local treatment measures which have proven to be useful, management of the extravasation should be symptomatic.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. CAUTION : Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. Nephrotoxic events (increased creatinine, impaired renal function, azotemia, and renal failure) are common with the parenteral administration of pentamidine isethionate. The administration of the drug should, therefore, be limited to the patients in whom Pneumocystis carinii has been demonstrated. The most frequently reported spontaneous adverse events (1 to 30%) reported in clinical trials, regardless of their relation to pentamidine isethionate therapy were as follows (n=424): Cardiovascular: Hypotension 5.0% Gastrointestinal: Anorexia/Nausea 5.9% Hematologic: Anemia Leukopenia Thrombocytopenia 1.2% 10.4% 2.6% Hepatic: Elevated liver function tests 8.7% Metabolic: Hypoglycemia 5.9% Neurologic: Confusion/hallucinations 1.7% Skin: Sterile abscess and/or necrosis, pain, or induration at the site of IM injection Rash 11.1% 3.3% Special Senses: Bad taste 1.7% Urogenital: Azotemia Elevated serum creatinine Elevated blood urea nitrogen Impaired renal function 8.5% 23.6% 6.6% 28.8% Adverse events with a frequency of less than 1% incidence were as follows (No causal relationship to treatment has been established for these adverse events): Body as a whole: Allergic reaction (i.e. urticaria, itching, rash), anaphylaxis, arthralgia, chills, extrapulmonary pneumocystosis, headache, night sweats, and Stevens-Johnson syndrome. Cardiovascular: Abnormal ST segment of electrocardiogram, cardiac arrhythmias, cerebrovascular accident, hypertension, palpitations, phlebitis, syncope, tachycardia, vasodilatation, vasculitis and ventricular tachycardia. Gastrointestinal: Abdominal pain, diarrhea, dry mouth, dyspepsia, hematochezia, hypersalivation, melena, pancreatitis, splenomegaly, and vomiting. Hematological: Defibrination, eosinophilia, neutropenia, pancytopenia, and prolonged clotting time. Hepatic: Hepatic dysfunction, hepatitis and hepatomegaly Metabolic: Hyperglycemia, hyperkalemia, hypocalcemia, and hypomagnesemia. Neurological: Anxiety, confusion, depression, dizziness, drowsiness, emotional lability, hypesthesia, insomnia, memory loss, neuropathy, nervousness, neuralgia, paranoia, paresthesia, peripheral neuropathy, seizure, tremors, unsteady gait, and vertigo. Respiratory system: Asthma, bronchitis, bronchospasm, chest congestion, chest tightness, coryza, cyanosis, eosinophilic or interstitial pneumonitis, gagging, hemoptysis, hyperventilation, laryngitis, laryngospasm, non-specific lung disorder, nasal congestion, pleuritis, pneumothorax, rales, rhinitis, shortness of breath, and tachypnea. Skin: Desquamation, dry and breaking hair, dry skin, erythema, dermatitis, pruritus, rash, and urticaria. Special senses: Blepharitis, blurred vision, conjunctivitis, contact lens discomfort, eye pain or discomfort, loss of hearing, loss of taste, and loss of smell. Urogenital: Flank pain, hematuria, incontinence, nephritis, renal dysfunction and renal failure. From post-marketing clinical experience with pentamidine isethionate, the following adverse events have been reported: cough, diabetes mellitus/ketoacidosis, dyspnea, infiltration (extravasation–see WARNINGS ), and torsades de pointes.
adverse reactions table
<table><tbody><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Cardiovascular:</paragraph><paragraph> Hypotension</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>5.0%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Gastrointestinal:</paragraph><paragraph> Anorexia/Nausea</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>5.9%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Hematologic:</paragraph><paragraph> Anemia</paragraph><paragraph> Leukopenia</paragraph><paragraph> Thrombocytopenia</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>1.2%</paragraph><paragraph>10.4%</paragraph><paragraph>2.6%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Hepatic:</paragraph><paragraph> Elevated liver function tests</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>8.7% </paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Metabolic:</paragraph><paragraph> Hypoglycemia</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>5.9%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Neurologic:</paragraph><paragraph> Confusion/hallucinations</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>1.7%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Skin:</paragraph><paragraph> Sterile abscess and/or necrosis,</paragraph><paragraph> pain, or induration at the site of</paragraph><paragraph> IM injection</paragraph><paragraph> Rash</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph> </paragraph><paragraph> </paragraph><paragraph>11.1%</paragraph><paragraph>3.3%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Special Senses:</paragraph><paragraph> Bad taste</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>1.7%</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Urogenital:</paragraph><paragraph> Azotemia</paragraph><paragraph> Elevated serum creatinine</paragraph><paragraph> Elevated blood urea nitrogen</paragraph><paragraph> Impaired renal function</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph> </paragraph><paragraph>8.5%</paragraph><paragraph>23.6%</paragraph><paragraph>6.6%</paragraph><paragraph>28.8%</paragraph></td></tr></tbody></table>
adverse reactions table
<table><tbody><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Body as a whole:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Allergic reaction (i.e. urticaria, itching, rash), anaphylaxis, arthralgia, chills, extrapulmonary pneumocystosis, headache, night sweats, and Stevens-Johnson syndrome.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Cardiovascular:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Abnormal ST segment of electrocardiogram, cardiac arrhythmias, cerebrovascular accident, hypertension, palpitations, phlebitis, syncope, tachycardia, vasodilatation, vasculitis and ventricular tachycardia.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Gastrointestinal:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Abdominal pain, diarrhea, dry mouth, dyspepsia, hematochezia, hypersalivation, melena, pancreatitis, splenomegaly, and vomiting.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Hematological:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Defibrination, eosinophilia, neutropenia, pancytopenia, and prolonged clotting time.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Hepatic:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Hepatic dysfunction, hepatitis and hepatomegaly</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Metabolic:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Hyperglycemia, hyperkalemia, hypocalcemia, and hypomagnesemia.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Neurological:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Anxiety, confusion, depression, dizziness, drowsiness, emotional lability, hypesthesia, insomnia, memory loss, neuropathy, nervousness, neuralgia, paranoia, paresthesia, peripheral neuropathy, seizure, tremors, unsteady gait, and vertigo.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Respiratory system:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Asthma, bronchitis, bronchospasm, chest congestion, chest tightness, coryza, cyanosis, eosinophilic or interstitial pneumonitis, gagging, hemoptysis, hyperventilation, laryngitis, laryngospasm, non-specific lung disorder, nasal congestion, pleuritis, pneumothorax, rales, rhinitis, shortness of breath, and tachypnea.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Skin:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Desquamation, dry and breaking hair, dry skin, erythema, dermatitis, pruritus, rash, and urticaria.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Special senses:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Blepharitis, blurred vision, conjunctivitis, contact lens discomfort, eye pain or discomfort, loss of hearing, loss of taste, and loss of smell.</paragraph></td></tr><tr><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Urogenital:</paragraph></td><td styleCode="Lrule Rrule Toprule Botrule" valign="top"><paragraph>Flank pain, hematuria, incontinence, nephritis, renal dysfunction and renal failure.</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.